(Q43182188)

15 November 2017

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors (English)

1 reference

15 November 2017

dasatinib monohydrate

1 reference

1 reference

1 reference

Faye M Johnson

1

1 reference

15 November 2017

Shruti Agrawal

2

1 reference

15 November 2017

Howard Burris

3

1 reference

15 November 2017

Lee Rosen

4

1 reference

15 November 2017

Navneet Dhillon

5

1 reference

15 November 2017

David Hong

6

1 reference

15 November 2017

Anne Blackwood-Chirchir

7

1 reference

15 November 2017

Feng R Luo

8

1 reference

15 November 2017

Oumar Sy

9

1 reference

15 November 2017

Sanjeev Kaul

10

1 reference

15 November 2017

Alberto A Chiappori

11

1 reference

15 November 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

15 November 2017

1 reference

15 November 2017

116

1 reference

15 November 2017

6

1 reference

15 November 2017

1582-1591

1 reference

SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy

15 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

QT and RR Intervals in Conscious and Anesthetized Guinea Pigs with Highly Varying RR Intervals and Given QTc-Lengthening Test Articles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24927

7 January 2021

Identifiers

DOI

10.1002/CNCR.24927

1 reference

15 November 2017

1 reference